Switching from Sertraline to Mirtazapine

Direct Recommendation

• The American Academy of Child and Adolescent Psychiatry recommends 2-4 week cross-tapers when switching between antidepressants, which a proposed 4-week regimen follows 4

Evidence Supporting the Approach

• Two high-quality trials (n=1231 participants) demonstrated no differences in efficacy or safety between switching from sertraline to mirtazapine versus augmenting sertraline with mirtazapine 1, 2, 3
• The decision between switching versus augmentation should be guided by tolerability during the overlap period and patient preference for monotherapy versus combination treatment 1, 2

Critical Safety Monitoring

• Monitor for serotonin syndrome during the overlap period when both medications are co-administered—symptoms include mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity, typically arising within 24-48 hours 4
• The risk of serotonin syndrome is low but requires clinical vigilance, particularly during weeks 1-3 when both drugs overlap 4

Alternative Consideration: Augmentation Strategy

• Consider maintaining both medications as augmentation therapy rather than completing the switch, since efficacy and safety are equivalent 1, 2, 3

Common Pitfalls to Avoid

• Do not abruptly stop sertraline at any point—maintain the gradual taper even if the patient feels improved on mirtazapine 4
• Do not combine with MAOIs—ensure no MAOI use within 14 days before or after this switch 4
• Monitor for early worsening—approximately 38% of patients do not achieve treatment response and 54% do not achieve remission with antidepressant switches, so close follow-up is essential 5